Core Viewpoint - The approval of the novel drug Amivantamab by Hansoh Pharmaceutical marks a significant breakthrough in the treatment of non-small cell lung cancer (NSCLC) in China, addressing a critical unmet medical need for postoperative patients with EGFR mutations [1][4]. Group 1: Drug Approval and Market Impact - On May 9, 2025, Hansoh Pharmaceutical announced that its self-developed class I new drug, Amivantamab, received approval from the National Medical Products Administration for use in adult patients with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations after tumor resection [1]. - The approval allows Amivantamab to break the monopoly of imported drugs in this field, achieving parallel coverage with imported drugs and marking a significant advancement for domestic innovative targeted drugs in the comprehensive treatment of NSCLC [3]. Group 2: Clinical Significance and Expert Opinions - Professor Cheng Ying from the Chinese Society of Clinical Oncology highlighted that the high recurrence rate of operable NSCLC patients post-surgery indicates a substantial unmet treatment need, and the approval of Amivantamab provides new hope for long-term survival [4]. - The third-generation EGFR-TKI has become the standard treatment for EGFR-mutated NSCLC, and the rapid development of innovative targeted drugs in China has allowed them to catch up with international drugs [4]. - Since its approval in 2020, Amivantamab has made significant progress in the treatment of NSCLC, and the new indication expands its use from first-line and second-line treatments to adjuvant therapy, solidifying its position in the treatment landscape [4].